MDS & Myeloproliferative Neoplasms

MDS & Myeloproliferative Neoplasms

A collection of features and news articles published in ASH Clinical News related to myelodysplastic syndromes and myeloproliferative neoplasms.

Luspatercept Reduces Anemia Severity, Improves Rate of Transfusion Independence in MDS

Compared with placebo, treatment with luspatercept improved the 12- to 16-week rate of red blood cell (RBC) transfusion independence in patients with lower-risk myelodysplastic...

FDA Grants Breakthrough Designation to APR-246 for MDS

The FDA granted breakthrough therapy designation to APR-246 in combination with azacitidine for the treatment of patients with myelodysplastic syndromes (MDS) and a TP53...
WIB_icon

Patients With SCD and TP53 Mutations May Develop Myeloid Malignancy After Unsuccessful AlloHCT

Population studies have shown that patients with sickle cell disease (SCD) who have undergone an unsuccessful allogeneic hematopoietic cell transplantation (alloHCT) have an increased...

Gilead Acquires Magrolimab Manufacturer Forty Seven, Inc. for $4.9 Billion

In its largest acquisition since purchasing Kite Pharma in 2017, Gilead announced that it has acquired cancer biotech Forty Seven, Inc. for $4.9 billion. Forty...

A 42-Item Frailty Index Improves Survival Prediction in Myelodysplastic Syndromes

In a recent Leukemia paper, researchers reported on a new 42-variable frailty index (FI) for patients with myelodysplastic syndromes (MDS), which appears to improve...
WIB_icon

Novel JAK2 Insertion/Deletion Mutation Associated With Unique MPN Overlap Syndrome

In a small study of patients with myeloproliferative neoplasms (MPNs), a novel JAK2 insertion/deletion mutation, which the investigators termed JAK2ex13InDel, was found to drive...

Perspectives on 2019’s New Hematology Drug Approvals

In 2019, the FDA approved several new therapies – or new indications for previously approved therapies – for people living with blood disorders, including...

Adding Navitoclax to Ruxolitinib in Ruxolitinib-Refractory Myelofibrosis Leads to Improvements in Spleen Volume, Symptom...

Watch our interview with Jacqueline Garcia, MD. More than one-third of patients with myelofibrosis (MF) who had not responded adequately to monotherapy with the FDA-approved...

Jacqueline Garcia: Evaluating Navitoclax for Myelofibrosis

Jacqueline S. Garcia, MD, shares results from a phase II study of navitoclax, an investigational disease-modifying therapy for the treatment of myelofibrosis, which appears...

Bomedemstat Reduces Symptom Burden for Patients With Myelofibrosis

Bomedemstat improved symptoms in most patients with myelofibrosis, with no dose-limiting toxicities or progressions to acute myeloid leukemia, according to results from the first...
Advertisement

Current Issue

April 2020, Volume 6, Issue 5

This issue examines current immunization guidelines for patients with hematologic disorders, considers medical education amid the coronavirus pandemic, and more.